Rhumbline Advisers increased its position in shares of Versartis, Inc. (NASDAQ:VSAR) by 4.2% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 35,388 shares of the biopharmaceutical company’s stock after acquiring an additional 1,420 shares during the quarter. Rhumbline Advisers owned about 0.10% of Versartis worth $618,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of the company. First Quadrant L P CA acquired a new position in Versartis in the second quarter valued at approximately $155,000. Bank of America Corp DE grew its holdings in Versartis by 46.3% during the 1st quarter. Bank of America Corp DE now owns 9,482 shares of the biopharmaceutical company’s stock worth $203,000 after acquiring an additional 3,001 shares during the period. UBS Group AG acquired a new stake in Versartis during the 1st quarter worth $367,000. Russell Investments Group Ltd. grew its holdings in Versartis by 125.9% during the 1st quarter. Russell Investments Group Ltd. now owns 18,160 shares of the biopharmaceutical company’s stock worth $387,000 after acquiring an additional 10,121 shares during the period. Finally, American International Group Inc. grew its holdings in Versartis by 20.7% during the 1st quarter. American International Group Inc. now owns 18,962 shares of the biopharmaceutical company’s stock worth $405,000 after acquiring an additional 3,250 shares during the period. 78.24% of the stock is currently owned by institutional investors and hedge funds.

Versartis, Inc. (NASDAQ:VSAR) opened at 2.45 on Monday. The stock has a 50 day moving average of $18.37 and a 200 day moving average of $18.36. The firm’s market cap is $87.17 million. Versartis, Inc. has a one year low of $2.35 and a one year high of $24.00.

Versartis (NASDAQ:VSAR) last posted its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported ($1.04) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.84) by ($0.20). Equities research analysts predict that Versartis, Inc. will post ($3.61) EPS for the current fiscal year.

VSAR has been the subject of several recent research reports. Morgan Stanley reiterated an “equal weight” rating and set a $4.00 target price (up previously from $3.00) on shares of Versartis in a research report on Friday, September 22nd. Cantor Fitzgerald restated an “overweight” rating and issued a $14.00 price target (down from $34.00) on shares of Versartis in a research report on Friday, September 22nd. Piper Jaffray Companies restated a “buy” rating and issued a $26.00 price target on shares of Versartis in a research report on Friday, September 8th. Zacks Investment Research cut Versartis from a “hold” rating to a “sell” rating in a research note on Wednesday, August 2nd. Finally, Cowen and Company cut Versartis from an “outperform” rating to a “market perform” rating and decreased their price objective for the stock from $45.00 to $3.00 in a research note on Friday, September 22nd. One research analyst has rated the stock with a sell rating, nine have given a hold rating and three have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $8.20.

In related news, major shareholder Life Sciences Maste Perceptive sold 2,130,000 shares of the business’s stock in a transaction on Friday, September 22nd. The shares were sold at an average price of $3.29, for a total value of $7,007,700.00. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 9.60% of the stock is owned by company insiders.

WARNING: This report was originally reported by Watch List News and is the property of of Watch List News. If you are reading this report on another publication, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The original version of this report can be read at https://www.watchlistnews.com/rhumbline-advisers-purchases-1420-shares-of-versartis-inc-vsar/1602180.html.

About Versartis

Versartis, Inc is an endocrine-focused biopharmaceutical company. The Company is engaged in developing a long-acting form of recombinant human growth hormone, somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease. The Company’s first indication for somavaratan is pediatric GHD.

Institutional Ownership by Quarter for Versartis (NASDAQ:VSAR)

Receive News & Ratings for Versartis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Versartis Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.